Fact CheckerSign in

NCT07524803Not yet recruiting

Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America(LUCAS-LATAM)

A Prospective Observational Study to Determine the Utility of Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America

Source: ClinicalTrials.gov · Last updated 13 Apr 2026

Brief summary (registry, in English)

Prospective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in patients with other high risk criteria to develop lung cancer. 2000 patients will be recruited in 4 LATAM countries (Mexico 700 pts, Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts). All patients will be ≥50years of age with one of the following additional inclusion criteria: a. exposure to wood smoke (at least 100 hours/year), b.family history of lung cancer in a first degree relative, c. COPD and/or emphysema, d. smokers with a tobacco index of 10 y or more. The exclusion criteria include: a. lung cancer diagnosis or other type of cancer 5 years prior to screening, b. loss of 10% of baseline weight 6 months before inclusion, c. ineligible for LDCT, d. life expectancy ≤5 years, and e. previous history of pulmonary nodules. The primary objective of the study is the utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM, with secondary objectives including: 1- Utility of qXR-LNMS (lung nodule malignancy score) of chest XRay for lung cancer risk assessment to exclude low risk patients from LDCT screening, 2- Utility of LDCT-based lung cancer screening in subjects with various risk profiles in LATAM, 3- Prevalence of lung nodules in the study population, 4-Mortality rate in the subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis).

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
2000 (estimated)
First submitted
6 Apr 2026
Start date
May 2026
Primary completion date
May 2030
Lead sponsor
Latin American Consortium for the Lung Cancer Research
Diseases
Lung cancer
NCT number
NCT07524803

What you commit to

  • Study type: Observational
  • Planned participants: 2000
  • From May 2026 to the primary completion date, May 2030
  • 2 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Lung cancer diagnosis or any other type of active cancer during the 5 years prior to the screening
  • Loss of 10% of the baseline weight during 6 months prior to study entry
  • Subjects with previous history of pulmonary nodules.

Other illness

  • Having a functional status, psychiatric condition or comorbidity that precludes curative treatment

Age

  • Life expectancy ≤5 years

Other

  • Incomplete clinical information
  • Any situation that makes the subject ineligible for LDCT

Who the study is looking for

  • 1\. Men and women ≥50 years of age and one of any of the following criteria:
  • Exposure to wood smoke (at least 100 hours per year)
  • A family history of lung cancer in first-degree relatives
  • A diagnosis of COPD and/or emphysema
  • Smokers with a tobacco index of 10 years or more

Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CTIC
Coordinator of this site? Confirm its status
BogotáColombiaUnknown status
Centro de Investigacion y Manejo del Cancer (CIMCA)
Coordinator of this site? Confirm its status
San JoséCosta RicaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.